Clicky

Clarity Pharmaceuticals Ltd(CU6)

Description: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.


Keywords: Medicine Cancer Clinical Medicine Imaging Treatment Of Cancer Prostate Cancer Radiopharmaceuticals Personalized Medicine Histopathology Medicinal Radiochemistry Somatostatin G Protein Coupled Receptors Pan Cancer

Home Page: www.claritypharmaceuticals.com

CU6 Technical Analysis

National Innovation Centre
Sydney, NSW 2015
Australia
Phone: 61 2 9209 4037


Officers

Name Title
Dr. Alan John Taylor Ph.D. Exec. Chairman
Dr. Colin David Biggin Ph.D. MD, CEO & Exec. Director
Mr. David K. Green BEc., CA Chief Financial Officer
Mr. Robert Vickery Company Sec.
Dr. Michael D. Ironside Director of Operations
Dr. Jeffrey Norenberg Chief Scientific Officer
Dr. Ellen van Dam Ph.D. Head of R&D
Mr. Shaemus Gleason Exec. VP of US Operations
Dr. Robert M. Miller Ph.D. Consultant Chief Medical Officer
Mr. William Cheadle Financial Controller

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.7448
Price-to-Sales TTM: 38.334
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks